WO2003068776A1 - Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine - Google Patents
Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine Download PDFInfo
- Publication number
- WO2003068776A1 WO2003068776A1 PCT/JP2003/001565 JP0301565W WO03068776A1 WO 2003068776 A1 WO2003068776 A1 WO 2003068776A1 JP 0301565 W JP0301565 W JP 0301565W WO 03068776 A1 WO03068776 A1 WO 03068776A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- triazolo
- pyrimidine derivatives
- adenosine
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003567903A JPWO2003068776A1 (ja) | 2002-02-15 | 2003-02-14 | [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体 |
AU2003211993A AU2003211993A1 (en) | 2002-02-15 | 2003-02-14 | (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-37819 | 2002-02-15 | ||
JP2002037819 | 2002-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003068776A1 true WO2003068776A1 (fr) | 2003-08-21 |
Family
ID=27678133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001565 WO2003068776A1 (fr) | 2002-02-15 | 2003-02-14 | Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2003068776A1 (fr) |
AU (1) | AU2003211993A1 (fr) |
WO (1) | WO2003068776A1 (fr) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029056A1 (fr) * | 2002-09-24 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Dérivé de [1,2,4]-triazolo[1,5]pyrimidine |
WO2004092173A3 (fr) * | 2003-04-09 | 2004-12-09 | Biogen Idec Inc | Antagonistes de recepteur d'adenosine a2a |
US7285550B2 (en) | 2003-04-09 | 2007-10-23 | Biogen Idec Ma Inc. | Triazolotriazines and pyrazolotriazines and methods of making and using the same |
US7517874B2 (en) | 2007-06-21 | 2009-04-14 | Cara Therapeutics, Inc. | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain |
US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
CN107922437A (zh) * | 2015-09-09 | 2018-04-17 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
WO2018166493A1 (fr) * | 2017-03-16 | 2018-09-20 | 江苏恒瑞医药股份有限公司 | Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales |
WO2020106558A1 (fr) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
US11161850B2 (en) | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
US11390624B2 (en) | 2019-01-29 | 2022-07-19 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
WO2022224180A1 (fr) * | 2021-04-23 | 2022-10-27 | Chong Kun Dang Pharmaceutical Corp. | Composé constituant un antagoniste du récepteur a2a de l'adénosine et composition pharmaceutique le comprenant |
US11673894B2 (en) | 2018-02-27 | 2023-06-13 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
RU2802866C2 (ru) * | 2018-09-12 | 2023-09-05 | Дизал (Цзянсу) Фармасьютикал Ко., Лтд. | Соединения триазоло-пиримидина и их применение |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998042711A1 (fr) * | 1997-03-24 | 1998-10-01 | Kyowa Hakko Kogyo Co., Ltd. | DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES |
WO2000017201A1 (fr) * | 1998-09-22 | 2000-03-30 | Kyowa Hakko Kogyo Co., Ltd. | DERIVES DE [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE |
-
2003
- 2003-02-14 JP JP2003567903A patent/JPWO2003068776A1/ja not_active Withdrawn
- 2003-02-14 AU AU2003211993A patent/AU2003211993A1/en not_active Abandoned
- 2003-02-14 WO PCT/JP2003/001565 patent/WO2003068776A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998042711A1 (fr) * | 1997-03-24 | 1998-10-01 | Kyowa Hakko Kogyo Co., Ltd. | DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES |
WO2000017201A1 (fr) * | 1998-09-22 | 2000-03-30 | Kyowa Hakko Kogyo Co., Ltd. | DERIVES DE [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029056A1 (fr) * | 2002-09-24 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Dérivé de [1,2,4]-triazolo[1,5]pyrimidine |
WO2004092173A3 (fr) * | 2003-04-09 | 2004-12-09 | Biogen Idec Inc | Antagonistes de recepteur d'adenosine a2a |
US7285550B2 (en) | 2003-04-09 | 2007-10-23 | Biogen Idec Ma Inc. | Triazolotriazines and pyrazolotriazines and methods of making and using the same |
US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
US7517874B2 (en) | 2007-06-21 | 2009-04-14 | Cara Therapeutics, Inc. | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain |
US8431565B2 (en) | 2007-06-21 | 2013-04-30 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
US8618290B2 (en) | 2008-02-01 | 2013-12-31 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
CN107922437A (zh) * | 2015-09-09 | 2018-04-17 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
JP7111733B2 (ja) | 2017-03-16 | 2022-08-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヘテロアリール[4,3-c]ピリミジン-5-アミン誘導体、その製造方法、およびその医薬の使用 |
TWI772386B (zh) * | 2017-03-16 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用 |
WO2018166493A1 (fr) * | 2017-03-16 | 2018-09-20 | 江苏恒瑞医药股份有限公司 | Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales |
JP2020510012A (ja) * | 2017-03-16 | 2020-04-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヘテロアリール[4,3−c]ピリミジン−5−アミン誘導体、その製造方法、およびその医薬の使用 |
US11312705B2 (en) | 2017-03-16 | 2022-04-26 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
RU2764655C2 (ru) * | 2017-03-16 | 2022-01-19 | Цзянсу Хэнжуй Медицин Ко., Лтд. | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ |
US11673894B2 (en) | 2018-02-27 | 2023-06-13 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
US11873304B2 (en) | 2018-05-18 | 2024-01-16 | Incyte Corporation | Fused pyrimidine derivatives as A2A/A2B inhibitors |
US11161850B2 (en) | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
US11999740B2 (en) | 2018-07-05 | 2024-06-04 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
RU2802866C2 (ru) * | 2018-09-12 | 2023-09-05 | Дизал (Цзянсу) Фармасьютикал Ко., Лтд. | Соединения триазоло-пиримидина и их применение |
RU2802866C9 (ru) * | 2018-09-12 | 2023-10-16 | Дизал (Цзянсу) Фармасьютикал Ко., Лтд. | Соединения триазоло-пиримидина и их применение |
EP3883575A4 (fr) * | 2018-11-20 | 2022-06-15 | Merck Sharp & Dohme Corp. | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
WO2020106558A1 (fr) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
US11390624B2 (en) | 2019-01-29 | 2022-07-19 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11884665B2 (en) | 2019-01-29 | 2024-01-30 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
WO2022224180A1 (fr) * | 2021-04-23 | 2022-10-27 | Chong Kun Dang Pharmaceutical Corp. | Composé constituant un antagoniste du récepteur a2a de l'adénosine et composition pharmaceutique le comprenant |
Also Published As
Publication number | Publication date |
---|---|
AU2003211993A1 (en) | 2003-09-04 |
JPWO2003068776A1 (ja) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003035639A1 (fr) | Compose de pyrimidine et composition medicinale contenant ledit compose | |
EP1700856A4 (fr) | Derive de thiazole | |
WO2003068776A1 (fr) | Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine | |
DE69820866D1 (de) | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE | |
NO20055510L (no) | 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister | |
EP1505068A4 (fr) | DERIVE DE PYRAZOLO(1,5-a)PYRIMIDINE ET INHIBITEUR DE LA NAD(P)H OXYDASE CONTENANT LEDIT DERIVE | |
WO2004056827A3 (fr) | Derives de pyrrolo-pyrazoles substitues constituant des inhibiteurs de kinases | |
DK1401837T3 (da) | Purinderivater som A2B-adenosinreceptorantagonister | |
BRPI0417478A (pt) | 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina | |
WO2006044958A8 (fr) | Derives de pyrazolo[1,5-alpha]pyrimidinyle utiles comme antagonistes vis-a-vis du recepteur du facteur de liberation de la corticotropine (crf) | |
NO20063231L (no) | Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer | |
MA26917A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine utiles comme agents immunosuppresseurs. | |
CY1105553T1 (el) | Υποκαταστατα 2-πυριμιδινυλιο-6,7,8,9-τετραϋδροπυριμιδο[1,2-α]πυριμιδιν-4-ονιο και 7-πυριμιδινυλιο-2,3-διυδροιμιδαζο[1,2-α]πυριμιδιν-5(1η)ονιο για νευροεκφυλιστικες διαταραχες | |
DE502004007000D1 (de) | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
NO20064166L (no) | Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter | |
PT1159279E (pt) | 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais | |
DE60130562D1 (de) | Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel | |
AU2003215753A1 (en) | Imidazopyridine derivatives as kinase inhibitors | |
WO2007143705A3 (fr) | Composés organiques | |
TWI349674B (en) | Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof | |
EP1477490A4 (fr) | Derive pyrrolopyrimidine | |
DK1534707T5 (da) | Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer | |
WO2000059449A3 (fr) | Derives de purine possedant une activite d'inhibition de la phosphodiesterase iv | |
MXPA03003923A (es) | Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas. | |
ZA200900165B (en) | 4-amino-3-arylamino-6-arylpyrazolo[3,4-D]pyrimidine derivatives, methods for their preparation and their use as antiviral agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003567903 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |